✦ LIBER ✦

Cost-Effectiveness of Bendamustine-Rituximab in First-Line Indolent NHL: A Patient-Level Simulation

✍ Scribed by Dewilde, S.; Woods, B.; Castaigne, J.G.; Parker, C.; Dunlop, W.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Cost-Effectiveness of Bendamustine-R

✍ Bertwistle, D.; Munakata, J.; Wehler, E.; Leyva, V.; Valencia, A.; Hernandez, A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

The Cost-Effectiveness of Bendamustine-R

✍ Bertwistle, D.; Munakata, J.; Wehler, E; Leyva, V.; Ariza, J.G.; Zambrano, C.; G 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

The Cost-Effectiveness of Bendamustine V

✍ Bertwistle, D.; Munakata, J.; Wehler, E.; Leyva, V.; Valencia, A.; Hernandez, A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

The Cost-Effectiveness of Sequential Fir

✍ de Groot, S.; Blommestein, H.; Redekop, W.; Oosterwijk, E.; Kiemeney, L.; Uyl- d 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

PCN86 Cost-Effectiveness of Rituximab in

✍ Gadaj, A.; Kalinowska, A.; Hawrylecka, D.; Holojda, J.; Krawcewicz, A.; Spychalo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Cost-effectiveness of First-line Antiepi

✍ Dan Chisholm; WHO-CHOICE 📂 Article 📅 2005 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 110 KB